Sugi Predict

Sugi Predict / Compounds / SCHEMBL2914575

SCHEMBL2914575

SCHEMBL2914575

Cc1c(F)ccc(C(=O)O)c1N

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 2/20 0.44
▸ GABRD O14764 2/20 0.44
▸ GABRA1 P14867 2/20 0.44
▸ GABRB1 P18505 2/20 0.44
▸ GABRG2 P18507 2/20 0.44
▸ GABRB3 P28472 2/20 0.44
▸ GABRA5 P31644 2/20 0.44
▸ GABRA3 P34903 2/20 0.44
▸ GABRA2 P47869 2/20 0.44
▸ GABRB2 P47870 2/20 0.44
▸ GABRA4 P48169 2/20 0.44
▸ GABRE P78334 2/20 0.44
▸ GABRA6 Q16445 2/20 0.44
▸ GABRG1 Q8N1C3 2/20 0.44
▸ GABRG3 Q99928 2/20 0.44
▸ GABRQ Q9UN88 2/20 0.44
▸ G6PD P11413 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ CASP6 P55212 1/20 0.42
▸ KDM4E B2RXH2 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31135141 1.00 GABRP (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL26641524 0.84 GABRP (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL26933598 0.84 DGAT1 (0.44) KDM4EKMT2AMEN1TDP1ALDH1A1
SCHEMBL24507277 0.84 CES2 (0.38) KMT2AESR2CES2CES1
SCHEMBL30560060 0.84 CES2 (0.38) KMT2AESR2CES2CES1
SCHEMBL31494238 0.83 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2921220 0.83 GABRP (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL14472134 0.81 CYP1A2 (0.44) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL5300551 0.79 ABL1 (0.49) CASP7KDM4EKMT2AALDH1A1MAPT
SCHEMBL1149742 0.79 KDM4E (0.48) GABRPGABRDGABRA1GABRB1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2025-11-20 — — US disclosed
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 — — US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 — — EP disclosed
CN-119487031-A Tryptanthrin derivatives and uses thereof 威森特生物公司 2025-02-18 — — CN disclosed
CN-111699176-B Quinazolinones as PARP14 inhibitors 里邦医疗公司 2025-02-14 — — CN disclosed
US-12215093-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2025-02-04 — — US disclosed
EP-3781550-B1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS INC (US) 2024-10-30 — — EP disclosed
CN-114671827-B O-benzoyl-sulfonyl imide derivative and application thereof 杭州百新生物医药科技有限公司 2024-09-20 — — CN disclosed
WO-2024129896-A1 INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 — — WO disclosed
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2024-05-09 — — US disclosed
US-9133164-B2 MIF inhibitors and their uses INNOV88 LLC (US) 2015-09-15 — — US disclosed
US-9133164-B2 MIF inhibitors and their uses INNOV88 LLC (US) 2015-09-15 — — US disclosed
US-20150065480-A1 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) 2015-03-05 — — US disclosed
US-20150065480-A1 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) 2015-03-05 — — US disclosed
CN-101528225-B 2-aminobenzoxazole carboxamides as 5HT3 modulators ALBANY MOLECULAR RES INC 2013-07-17 — — CN disclosed
WO-2012142498-A2 MIF INHIBITORS AND THEIR USES INNOVIMMUNE BIOTHERAPEUTICS, INC. (US) 2012-10-18 — — WO disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 — — US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 — — EP disclosed
CN-101528225-A 2-aminobenzoxazole carboxamides as 5HT3 modulators AMR TECHNOLOGY INC (US) 2009-09-09 — — CN disclosed
WO-2007028789-A1 QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-03-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150316-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 GABRP 295/4885GABRD 264/4885GABRA1 180/4885
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 GABRP 3537/4885GABRD 4100/4885GABRA1 4016/4885
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K GABRP 1282/4885GABRD 1489/4885GABRA1 1956/4885
US-20250353829-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 GABRP 295/4885GABRD 264/4885GABRA1 180/4885
US-12215093-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 GABRP 295/4885GABRD 264/4885GABRA1 180/4885
US-20150065480-A1 MIF INHIBITORS AND THEIR USES MIF, SERPINB1, HMGB2 GABRP 3286/4885GABRD 4337/4885GABRA1 3781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.